AAU
0.005
66.7%
VML
0.002
-33.3%
IFG
0.008
60%
FCT
0.013
-23.5%
BLZ
0.003
50%
CXU
0.007
-22.2%
CVR
0.24
45.5%
AW1
0.04
-21.6%
HIO
0.023
43.8%
AYT
0.004
-20%
SHN
0.01
42.9%
BYH
0.004
-20%
DTR
0.078
41.8%
EVR
0.004
-20%
DTM
0.004
33.3%
NRX
0.013
-18.8%
WYX
0.027
28.6%
RON
0.16
-17.9%
4DS
0.065
27.5%
PCL
0.01
-16.7%
ROG
0.005
25%
PGY
0.005
-16.7%
TOU
0.02
25%
VEN
0.005
-16.7%
G50
0.155
24%
FML
0.355
-15.5%
RCE
0.355
20.3%
NHE
0.011
-15.4%
FG1
0.03
20%
FGR
0.028
-15.2%
IPT
0.006
20%
AN1
0.006
-14.3%
OLL
0.018
20%
ARV
0.006
-14.3%
RC1
0.006
20%
GLL
0.006
-14.3%
WBE
0.006
20%
HMD
0.012
-14.3%
AZ9
0.031
19.2%
MKL
0.012
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PYC Therapeutics (ASX:PYC): Reports vision improvement in multiple RP11 patients

PYC Therapeutics (ASX:PYC) has developed the only clinical-stage investigational drug candidate designed specifically for patients with the blinding eye disease Retinitis Pigmentosa type 11 (RP11).

👁️ PYC recently reported an improvement in vision in 2 patients with RP11
📣 PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024
🧪 PYC is now preparing for a registrational trial that will be designed to support a new drug application and commercial launch of this drug candidate 4

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240812/pdf/066j27mrjnft47.pdf

Write to us
  • © 2025 Copyright
  • The Stock Network
  • All rights reserved